RxDoctor Payments Data

Claudio Manubens, MD

Cardiovascular Disease · Davenport, FLNPI 1992700363

Payments from drug & device makers

$21,610in general payments, 2019–2025

Across 384 payments — averaging $56.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$9K
  • Biotronik Inc.$3K
  • Medtronic$995
  • Abbott$971
  • Amgen$939
  • Johnson & Johnson$754
  • plus $6K from 34 others

What the payments were for

  • Travel & lodging$1,0998%
  • Food & beverage$11,77190%
  • Education$2412%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,610 in reported general payments places this provider in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$2,327,631
Medicare patients
1,758
Services billed
20,905

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,301$763,528
AdempasRiociguat19$329,293
XareltoRivaroxaban312$233,385
Repatha SureclickEvolocumab159$129,995
JardianceEmpagliflozin232$122,234
EntrestoSacubitril/Valsartan171$110,014
TrulicityDulaglutide92$96,757
TivicayDolutegravir Sodium29$66,712
JanuviaSitagliptin Phosphate133$59,248
OzempicSemaglutide42$42,693
Potassium Chloride1,074$39,350
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$38,314
MyrbetriqMirabegron80$36,851
Atorvastatin Calcium2,274$30,810
Breo ElliptaFluticasone/Vilanterol67$28,217

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$241$763,5281,301 claims
BayerAdempas$343$329,29319 claims
Johnson & JohnsonXarelto$754$233,385312 claims
Boehringer IngelheimJardiance, Tradjenta$86$141,139282 claims
Lilly USA, LLCTrulicity, Mounjaro$21$115,474114 claims
NovartisEntresto$573$110,014171 claims
MerckJanuvia$227$59,248133 claims
Astellas Pharma US IncMyrbetriq$81$36,85180 claims
Smith+NephewSantyl$127$27,73927 claims
AstraZenecaBreztri Aerosphere$277$15,22723 claims
Eisai Inc.Fycompa$16$14,26417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Davenport

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →